Why the study?
Do novel oral anticoagulants prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation compared to warfarin?
Do novel oral anticoagulants prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation compared to warfarin?
This review summarizes the mechanisms, clinical use, and pivotal trial evidence for novel oral anticoagulants as an alternative to warfarin in patients with nonvalvular atrial fibrillation.
May support preferring NOACs over warfarin in nonvalvular AF with lower intracranial bleeding; leaves open optimal agent selection and long-term real-world data.
The increasing availability of novel oral anticoagulants (NOAC) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) offers alternatives for patients currently prescribed warfarin. This article provides a brief overview on the mechanism and clinical use of these drugs as well as a review of the pivotal clinical trials providing the basis for each agent's safety and efficacy. While these agents are currently Food and Drug Administration (FDA) approved for anticoagulation of patients with nonvalvular AF, additional studies continually emerge offering further insight into the application of these agents in other areas.
No takes yet. Share an insight, caveat, or question.
Madan et al. (2014) conducted a review in Nonvalvular atrial fibrillation. Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Warfarin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: